ZA948025B - Methods for treating resistant neoplasms - Google Patents

Methods for treating resistant neoplasms

Info

Publication number
ZA948025B
ZA948025B ZA948025A ZA948025A ZA948025B ZA 948025 B ZA948025 B ZA 948025B ZA 948025 A ZA948025 A ZA 948025A ZA 948025 A ZA948025 A ZA 948025A ZA 948025 B ZA948025 B ZA 948025B
Authority
ZA
South Africa
Prior art keywords
chem
methods
treating resistant
resistant neoplasms
neoplasms
Prior art date
Application number
ZA948025A
Other languages
English (en)
Inventor
Srinivasan Chandrasekhar
Anne Hollins Dantzig
Robert Lee Shepard
James Jacob Starling
Mark Alan Winter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA948025B publication Critical patent/ZA948025B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
ZA948025A 1993-10-15 1994-10-13 Methods for treating resistant neoplasms ZA948025B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13767893A 1993-10-15 1993-10-15

Publications (1)

Publication Number Publication Date
ZA948025B true ZA948025B (en) 1996-04-15

Family

ID=22478575

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948025A ZA948025B (en) 1993-10-15 1994-10-13 Methods for treating resistant neoplasms

Country Status (17)

Country Link
EP (1) EP0652004B1 (da)
JP (1) JPH07149638A (da)
KR (1) KR950010891A (da)
CN (1) CN1108094A (da)
AT (1) ATE220323T1 (da)
AU (1) AU670518B2 (da)
CA (1) CA2118096A1 (da)
CZ (1) CZ253694A3 (da)
DE (1) DE69430940T2 (da)
DK (1) DK0652004T3 (da)
ES (1) ES2179063T3 (da)
HU (1) HUT71237A (da)
IL (1) IL111287A0 (da)
NO (1) NO943874L (da)
PT (1) PT652004E (da)
RU (1) RU94037233A (da)
ZA (1) ZA948025B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
EP0777476A4 (en) * 1994-08-22 1999-06-23 Lilly Co Eli METHOD FOR INHIBITING ENDOMETRIUM CANCER
ZA956988B (en) * 1994-08-22 1997-02-21 Lilly Co Eli Methods of inhibiting primary endometrial hyperplasia.
JPH10505348A (ja) * 1994-08-31 1998-05-26 イーライ・リリー・アンド・カンパニー 耐性腫瘍の同定および治療方法
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
EP0773217A1 (en) * 1995-11-07 1997-05-14 Eli Lilly And Company Benzothiphene derivatives for treating resistant tumors
CZ235398A3 (cs) * 1996-01-29 1999-02-17 Eli Lilly And Company Farmaceutický prostředek pro inhibici muskuloaponeurotických fibromatóz savců zvláště lidí
ID15917A (id) * 1996-01-29 1997-08-21 Lilly Co Eli Metode untuk menghambat tumor usus besar
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
CZ341297A3 (cs) * 1996-10-30 1998-05-13 Eli Lilly And Company Způsob zlepšení léčby nebo profylaxe rakoviny prsu
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
EP1392304A1 (en) * 2001-05-10 2004-03-03 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostate cancer
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
CZ253694A3 (en) 1995-05-17
DK0652004T3 (da) 2002-09-02
AU670518B2 (en) 1996-07-18
KR950010891A (ko) 1995-05-15
EP0652004A1 (en) 1995-05-10
DE69430940D1 (de) 2002-08-14
ES2179063T3 (es) 2003-01-16
NO943874D0 (no) 1994-10-13
CN1108094A (zh) 1995-09-13
AU7578694A (en) 1995-05-04
RU94037233A (ru) 1996-08-27
HUT71237A (en) 1995-11-28
ATE220323T1 (de) 2002-07-15
NO943874L (no) 1995-04-18
HU9402961D0 (en) 1995-02-28
CA2118096A1 (en) 1995-04-16
PT652004E (pt) 2002-10-31
IL111287A0 (en) 1994-12-29
DE69430940T2 (de) 2003-04-03
JPH07149638A (ja) 1995-06-13
EP0652004B1 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
IL112048A0 (en) Methods of inhibiting thrombin
ZA948029B (en) Methods for inhibiting endometriosis
SG46324A1 (en) Methods of inhibiting uterine fibrosis
HU9403667D0 (en) Methods of inhibiting seborrhea and acne
HU9402961D0 (en) Methods for treating resistant neoplasms
ZA948028B (en) Methods for inhibiting cartilage degradation
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.